Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Norethindrone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR known ✓ | P06401 | 5/20 | 0.92 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.92 |
| ▸ | LMNA | P02545 | 5/20 | 0.92 |
| ▸ | ABCB11 | O95342 | 4/20 | 0.92 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.92 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.92 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.92 |
| ▸ | ESR1 | P03372 | 2/20 | 0.92 |
| ▸ | SHBG | P04278 | 2/20 | 0.92 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.92 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.92 |
| ▸ | TSHR | P16473 | 1/20 | 0.92 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.92 |
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | AR | P10275 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.69 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Norethindrone SCHEMBL11291575 | 0.97 | CYP3A4 (0.94) | CYP3A4LMNAPGRABCB11CYP2C19 | |
| Norethindrone SCHEMBL19510084 | 0.96 | CYP3A4 (1.00) | CYP3A4LMNAPGRABCB11CYP2C19 | |
| Norethindrone SCHEMBL23390 | 0.96 | CYP3A4 (1.00) | CYP3A4LMNAPGRABCB11CYP2C19 | |
| Norethindrone SCHEMBL11781372 | 0.96 | CYP3A4 (1.00) | CYP3A4LMNAPGRABCB11CYP2C19 | |
| Norethindrone SCHEMBL7768886 | 0.96 | CYP3A4 (1.00) | CYP3A4LMNAPGRABCB11CYP2C19 | |
| Norethindrone SCHEMBL24476231 | 0.96 | CYP3A4 (1.00) | CYP3A4LMNAPGRABCB11CYP2C19 | |
| Norethindrone SCHEMBL14074493 | 0.96 | CYP3A4 (1.00) | CYP3A4LMNAPGRABCB11CYP2C19 | |
| Norethindrone SCHEMBL14577661 | 0.96 | CYP3A4 (1.00) | CYP3A4LMNAPGRABCB11CYP2C19 | |
| Norethindrone SCHEMBL6834811 | 0.96 | CYP3A4 (1.00) | CYP3A4LMNAPGRABCB11CYP2C19 | |
| Norethindrone SCHEMBL5021649 | 0.96 | CYP3A4 (1.00) | CYP3A4LMNAPGRABCB11CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8143 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091041-A1 | Methods of Treating Heavy Menstrual Bleeding | ABBVIE INC (US) | 2026-04-02 | — | — | US | claimed |
| US-20260091036-A1 | Dosing Regimens for Elagolix | ABBVIE INC (US) | 2026-04-02 | — | — | US | claimed |
| CN-121586586-A | Process for preparing ophthalmic compositions of low solubility materials | 全福生物科技股份有限公司 | 2026-02-27 | — | — | CN | claimed |
| US-12551447-B2 | Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists | Sumitomo Pharma Co., Ltd. (JP) | 2026-02-17 | — | — | US | claimed |
| US-20260000613-A1 | INJECTABLE CONTROLLED-RELEASE FORMULATIONS OF PROGESTOGEN DRUGS | FORDOZ PHARMA CORP. (US) | 2026-01-01 | — | — | US | claimed |
| EP-4643858-A1 | METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF UTERINE DISEASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-11-05 | — | — | EP | claimed |
| US-12390476-B2 | Multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogen | Arkady, Rubin (US) | 2025-08-19 | — | — | US | claimed |
| US-20250213486-A1 | Solid Pharmaceutical Formulations for Treating Endometriosis, Uterine Fibroids, Polycystic Ovary Syndrome or Adenomyosis | ABBVIE INC. (US) | 2025-07-03 | — | — | US | claimed |
| US-20250152556-A1 | ETRASIMOD FOR USE IN TREATING S1P1 RECEPTOR-ASSOCIATED DISORDERS IN COMBINATION WITH HORMONE TREATMENT | ARENA PHARMACEUTICALS, INC. (US) | 2025-05-15 | — | — | US | claimed |
| CN-119355175-B | Method for non-targeted detection of 86 hormone interferents in aquatic ecosystem, hormone interferent ecological risk evaluation method and optimal control sequencing method | 成都市食品检验研究院 | 2025-04-29 | — | — | CN | claimed |
| EP-0309263-A2 | Hormone composition and use | JENCAP RESEARCH LIMITED (CA) | 1989-03-29 | — | — | EP | claimed |
| EP-0301850-A2 | LHRH antagonist analogs and 19-nor-progestational steroids for therapy | SYNTEX (U.S.A.) INC. (US) | 1989-02-01 | — | — | EP | claimed |
| WO-1988007370-A1 | COMPOSITIONS AND METHODS OF EFFECTING CONTRACEPTION AND CONTROL OF BREAST CANCER | APPLIED MEDICAL RESEARCH, LTD. (US) | 1988-10-06 | — | — | WO | claimed |
| CN-88101379-A | Methods and compositions for effecting contraception | — | 1988-10-05 | — | — | CN | claimed |
| EP-0235090-A1 | Composition useful in the treatment of estrogen deficiencies | WARNER-LAMBERT COMPANY (US) | 1987-09-02 | — | — | EP | claimed |
| EP-0226679-A1 | Contraceptive method and kit | WARNER-LAMBERT COMPANY (US) | 1987-07-01 | — | — | EP | claimed |
| US-4346709-A | Drug delivery devices comprising erodible polymer and erosion rate modifier | ALZA CORPORATION (US) | 1982-08-31 | — | — | US | claimed |
| US-4244949-A | Manufacture of long term contraceptive implant | THE POPULATION COUNCIL, INC. (US) | 1981-01-13 | — | — | US | claimed |
| US-3942641-A | Dispensing packages containing novel cyclic progestogen-interrupted estrogen oral contraceptive regimens | SYNTEX CORPORATION (PM) | 1976-03-09 | — | — | US | claimed |
| US-3932635-A | Novel cyclic progestogen-interrupted estrogen oral contraceptive regimens | SYNTEX CORPORATION (PM) | 1976-01-13 | — | — | US | claimed |